Chione Ltd - Jun 12, 2023 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
10%+ Owner
Signature
Chione Limited, by /s/ Shalom Leaf, as attorney-in fact by power of attorney
Stock symbol
ACRV
Transactions as of
Jun 12, 2023
Transactions value $
-$72,412
Form type
4
Date filed
6/14/2023, 06:33 PM
Previous filing
Nov 21, 2022
Next filing
Jun 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Sale -$24.7K -2K -0.05% $12.34 3.85M Jun 12, 2023 Direct F1, F2, F3, F4, F5
transaction ACRV Common Stock Sale -$36.9K -3K -0.08% $12.30 3.85M Jun 13, 2023 Direct F1, F2, F3, F4, F5
transaction ACRV Common Stock Sale -$10.8K -893 -0.02% $12.13 3.85M Jun 14, 2023 Direct F1, F2, F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The prices reported in Column 4 are weighted average prices. The 2,000 shares referred to in the first row of Column 4 were sold at prices ranging from $12.165 to $12.49, inclusive. The 3,000 shares referred to in the second row of Column 4 were sold at prices ranging from $12.03 to $12.55, inclusive. The 893 shares referred to in the third row of Column 4 were sold at prices ranging from $12.01 T0 $12.47, inclusive.
F2 The reporting persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within each of the ranges set forth in footnote 1 above.
F3 Shares owned directly by Chione Limited ("Chione"). Chione's directors, Marcin Czernik, Andreas Hadjimichael and Anastasis Nikolaou, and its sole shareholder, Wiaczeslaw Smolokowski, may be deemed to share beneficial ownership of the shares directly owned by Chione.
F4 Each reporting person states that neither the filing of this Form 4 nor anything herein shall be deemed an admission that such person is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Act"), or otherwise, the beneficial owner of any securities covered by this Form 4. Each reporting person disclaims beneficial ownership of the securities covered by this statement, except to the extent of the pecuniary interest of such person in such securities.
F5 Each reporting person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for purposes of Section 13(d) or 13(g) of the Act. Each reporting person declares that neither the filing of this Form 4 nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, a member of a group with respect to the issuer or securities of the issuer.

Remarks:

Exhibit Index Exhibit 24.1 - Power of Attorney, dated October 10, 2022, made by Marcin Czernik and Chione Limited in favor of Shalom Leaf (filed with the Form 3, filed on behalf of Chione Limited et al on 11/09/22) Exhibit 24.2 - Power of Attorney, dated October 10, 2022, made by Andreas Hadjimichael and Chione Limited in favor of Shalom Leaf (filed with the Form 3, filed on behalf of Chione Limited et al on 11/09/22) Exhibit 24.3 - Power of Attorney, dated October 10, 2022, made by Wiaczeslaw Smolokowski in favor of Shalom Leaf (filed with the Form 3, filed on behalf of Chione Limited et al on 11/09/22) Exhibit 24.4 - Power of Attorney, dated October 10, 2022, made by Anastasis Nikolaou in favor of Shalom Leaf (filed with the Form 3/A, filed on behalf of Chione Limited et al on 11/14/22) Exhibit 99.1 - Joint Filer Information (filed with the Form 3/A, filed on behalf of Chione Limited et al on 11/14/22) Exhibit 99.2 - Joint Filing Agreement (filed with the Form 3/A, filed on behalf of Chione Limited et al on 11/14/22)